Monte Rosa Therapeutics (GLUE) Return on Capital Employed (2021 - 2026)

Monte Rosa Therapeutics' Return on Capital Employed history runs 6 years deep, the most recent figure standing at 28.43% for Q1 2026.

• On a quarterly basis, Return on Capital Employed fell 2784.0% year-over-year to 28.43% in Q1 2026; TTM through Mar 2026 was 28.43%, a 2784.0% decrease from a year earlier, with the FY2025 full-year figure at 14.28%, up 2357.0% from the prior year.
• Return on Capital Employed declined to 28.43% in Q1 2026 per GLUE's latest filing, from 13.9% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 4.47% in Q2 2025 and bottomed at 61.95% in Q4 2023.
• The 5-year median for Return on Capital Employed is 34.64% (2022), against an average of 32.69%.
• Across the five-year window, Return on Capital Employed surged 5843 bps in 2025 and sank 2784 bps in 2026, its largest moves.
• Year by year, Return on Capital Employed stood at 34.64% in 2022, then slumped by 79 bps to 61.95% in 2023, then jumped by 40 bps to 36.88% in 2024, then jumped by 62 bps to 13.9% in 2025, then tumbled by 105 bps to 28.43% in 2026.
• Per Business Quant, the three latest GLUE Return on Capital Employed figures stand at 28.43% (Q1 2026), 13.9% (Q4 2025), and 2.44% (Q3 2025).